Moleculin Biotech (NASDAQ:MBRX – Get Free Report) and ProQR Therapeutics (NASDAQ:PRQR – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, valuation, dividends, institutional ownership and analyst recommendations.
Profitability
This table compares Moleculin Biotech and ProQR Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Moleculin Biotech | N/A | -87.19% | -68.91% |
| ProQR Therapeutics | -260.75% | -61.58% | -19.43% |
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Moleculin Biotech and ProQR Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Moleculin Biotech | 0 | 0 | 3 | 0 | 3.00 |
| ProQR Therapeutics | 0 | 0 | 4 | 0 | 3.00 |
Volatility & Risk
Moleculin Biotech has a beta of 1.84, suggesting that its share price is 84% more volatile than the S&P 500. Comparatively, ProQR Therapeutics has a beta of 0.42, suggesting that its share price is 58% less volatile than the S&P 500.
Insider & Institutional Ownership
15.5% of Moleculin Biotech shares are held by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are held by institutional investors. 6.7% of Moleculin Biotech shares are held by insiders. Comparatively, 8.4% of ProQR Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Earnings & Valuation
This table compares Moleculin Biotech and ProQR Therapeutics’ top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Moleculin Biotech | N/A | N/A | -$29.77 million | N/A | N/A |
| ProQR Therapeutics | $10.31 million | 15.78 | -$30.43 million | ($0.37) | -5.41 |
Moleculin Biotech has higher earnings, but lower revenue than ProQR Therapeutics.
Summary
ProQR Therapeutics beats Moleculin Biotech on 6 of the 10 factors compared between the two stocks.
About Moleculin Biotech
Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.
About ProQR Therapeutics
ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
